COVID-19 outcomes in patients with multiple sclerosis: Understanding changes from 2020 to 2022.
Lina JeantinElisabeth MaillartPierre LabaugeElisabeth MaillartJérôme de SezeHélène ZéphirJean PelletierPhilippe KerschenDamien BiottiOlivier HeinzlefLaurent GuillotonCaroline BensaMarie ThéaudinBertrand AudoinOlivier CasezAude MauroussetDavid LaplaudEric BergerChristine Lebrun-FrenayBertrand BourrePierre BrangerBruno StankoffPierre ClavelouEric ThouvenotEric ManchonThibault MoreauFrançois SellalMickaël ZedetCaroline PapeixCéline LouaprePublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2024)
In pwMS, consistent risk factors were anti-CD20 therapies and neurological disability, emerging as vital drivers of COVID-19 severity regardless of wave, period, or vaccination status.